BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240820
DTEND;VALUE=DATE:20240823
DTSTAMP:20260515T172643
CREATED:20240423T145330Z
LAST-MODIFIED:20240423T145330Z
UID:39018-1724112000-1724371199@www.pharmajournalist.com
SUMMARY:2nd RNA Assay Development Screening Summit
DESCRIPTION:There has been many exciting investments and advancements in the field\, such as Atavistik Bio raising an additional $40 million to advance their small molecule therapeutics and Servier and Base4 expanding their partnership to accelerate development of neuroscience drugs. However\, the discovery of potent RNA targeting small molecules is plagued by limited robust assays and screening methods for understanding the RNA target structure as well as the mechanism of action of the small molecule drugs. \nHence\, this August the 2nd RNA Assay Development & Screening Summit returns to Boston as the first and only industry dedicated event on developing sensitive\, and reproducible assay and screening methods. With 70% brand new speaker faculty from key stakeholder companies as well as new companies entering the field\, including the likes of AstraZeneca\, Arrakis Therapeutics\, Molecure\, Wayfinder Biosciences\, Biogen and more\, access the latest strategies for developing reproducible and sensitive assay and screening methods. \nDownload the free brochure or book your place now\, early birds are still available!
URL:http://www.pharmajournalist.com/event/2nd-rna-assay-development-screening-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240820
DTEND;VALUE=DATE:20240823
DTSTAMP:20260515T172643
CREATED:20240515T095414Z
LAST-MODIFIED:20240515T095414Z
UID:39112-1724112000-1724371199@www.pharmajournalist.com
SUMMARY:5th Gene Therapy Immunogenicity Summit
DESCRIPTION:Optimize Safety & De-Risk Efficacy of Viral Vector-Based Gene Therapies \nThe success of gene therapy hinges on overcoming the immunogenicity challenges of viral vectors. With more viral vector-based gene therapies progressing through the pipeline\, we need to seek solutions to this critical bottleneck ‘here and now’. \nThe 5th Gene Therapy Immunogenicity Summit is returning to Boston this August\, bringing together 100+ immunogenicity experts responsible for predicting\, measuring\, and mitigating immune response. Join your colleagues as they share their learnings and gain key insights on: \n \n\nEffective approaches to promote AAV safety whilst maintaining efficacy\nPreventing the bottlenecks of the potential slowdown of gene therapy development\n\nAccess specific\, case-study-led examples across immunogenicity and ask the big-hitting immunology questions to your peers actively working in the space to make clinically safe and effective gene therapies a reality. \n\nPredicting and mitigating against complement activation and other toxicity issues with Ask Bio\, Takeda\, and Novartis\nValidating novel Immunoassays\, bioanalytical and biodistribution technology with Astellas Gene Therapies and Boehringer Ingelheim\nUnderstanding possible risks around exacerbation of both the innate and adaptive immune response with Roche and Tenaya Therapeutics\nExploring the practicalities of AAV redosing through an immunology lens with the University of Indiana and Adolore Biotherapeutics\nExamine the immunogenicity risks specific to gene editing approached as momentum in the field increases with CRISPR and Modalis Therapeutics
URL:http://www.pharmajournalist.com/event/5th-gene-therapy-immunogenicity-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240820
DTEND;VALUE=DATE:20240823
DTSTAMP:20260515T172643
CREATED:20240523T112419Z
LAST-MODIFIED:20240529T133152Z
UID:39154-1724112000-1724371199@www.pharmajournalist.com
SUMMARY:2nd ADC Linker & Conjugation Summit
DESCRIPTION:With Eli Lilly’s acquisition of Mablink and Novartis’ investment in Tagworks\, both centering on their innovative linker and conjugation technologies – optimizing linker chemistry and diversifying conjugation technologies to increase stability and selectivity are becoming increasingly more attractive to ADC developers as they strive for a competitive edge over their peers. \n \nAs part of the World ADC Series\, the 2nd ADC Linker & Conjugation Summit is the only forum exclusively focused on enhancing your linker and conjugation chemistry. With 100+ attendees ranging from boots-on-the-ground scientists working on improving linker & conjugation chemistries daily\, through to more senior directors\, this conference is the optimal combination of knowledge sharing and networking. \nLeave this summit with the confidence to innovate hydrophilic linkers that help prevent aggregation\, enhance stability in linkers & conjugations to ensure tumor targeting and hone site-specific conjugations to guarantee homogenous DAR\, all to ultimately ensure ADC stability and widen therapeutic index.
URL:http://www.pharmajournalist.com/event/2nd-adc-linker-conjugation-summit/
LOCATION:W Boston\, 100 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
END:VCALENDAR